
Celebrating TOP EMPLOYER Certification for Two Consecutive Years
25/02/2025
employees
countries in which the Group’s
medicines are distributed 20%
of revenue from brand-name medicines
invested in R&D each year
euros in revenue in 2023/2024 including
€4.5 billion for brand-name medicines
and €1.4 billion for generic activities
Oncology, Cardiometabolism &
Venous Diseases, Neurology